Adempas (Riociguat) for Pulmonary Hypertension | myPHteam

Connect with others who understand.

sign up Log in
About myPHteam
Powered By

Adempas is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise and function in adult cases of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Adempas may be referred to by its drug name, riociguat.

Adempas is in a class of drugs called soluble guanylate cyclase stimulators (SGCS). Adempas stimulates the action of an enzyme called soluble guanylate cyclase, which works to dilate blood vessels. In cases of pulmonary hypertension, Adempas is believed to work by dilating the pulmonary arteries.

How do I take it?
Prescribing information states that Adempas is taken three times a day. Due to its ability to cause severe birth defects, Adempas is only available to female consumers through a limited distribution program called Adempas Risk Evaluation and Mitigation Strategies (REMS) Program.

Adempas comes in tablet form.

Side effects
The FDA-approved label for Adempas lists common side effects including headache, dizziness, hypotension (low blood pressure), upset stomach, stomach pain, anemia, gastric reflux, nausea, diarrhea, vomiting, and constipation.

Rare but serious side effects listed for Adempas include severe birth defects, bleeding, severe hypotension, and pulmonary edema (fluid in the lungs).

For more details about this treatment, visit:

Adempas — Bayer

Soluble Guanylate Cyclase Stimulators (SGCSs) — Pulmonary Hypertension Association UK

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in